Alkermes Shows Improved Relative Strength; Still Shy Of Benchmark

Blockhead

2024-10-14

The Relative Strength (RS) Rating for Alkermes (ALKS) moved up into a new percentile Monday, as it got a lift from 64 to 76.

↑ X

How To Find The Best IPO Stocks

See All Videos

NOW PLAYING How To Find The Best IPO Stocks

IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.

Decades of market research reveals that the best stocks often have an 80 or better RS Rating as they launch their largest price moves. See if Alkermes can continue to rebound and hit that benchmark.

Can You Really Time The Stock Market?

Alkermes is trying to complete a cup without handle with a 32.88 buy point. See if the stock can break out in volume at least 40% above average.

The company reported negative growth for both the top and bottom lines last quarter. Alkermes is expected to release its next quarterly numbers on or around Oct. 23.

The company holds the No. 19 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX) and United Therapeutics (UTHR) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Technical Action?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2475137873"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2475137873\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2475137873?lang=zh_TW&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU6-150x150.jpg","is_english":true,"pubTime":"2024-10-14 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475137873","market":"us","top_or_hot":-1,"title":"Alkermes Shows Improved Relative Strength; Still Shy Of Benchmark","media":"Blockhead","content":"<html><body><div>\n<p>The Relative Strength (RS) Rating for <b>Alkermes</b> (ALKS) moved up into a new percentile Monday, as it got a lift from 64 to 76.</p>\n<span>\n<span>\n<span jw-video-key=\"ehvvvOwx\" vid-authors=\"RACHEL FOX\" vid-cat=\"Investor's Corner\" vid-date=\"01/23/2024\" vid-date-tmsp=\"1706014196\" vid-dom-id=\"8911995-670d5648cd096\" vid-id=\"8911995\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/01/IC_IPOstocks-640x360.png\" vid-name=\"How To Find The Best IPO Stocks\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/ehvvvOwx.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nHow To Find The Best IPO Stocks\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>How To Find The Best IPO Stocks</span>\n</span>\n</span>\n</span>\n</span>\n<p>IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.</p>\n<p>Decades of market research reveals that the best stocks often have an 80 or better RS Rating as they launch their largest price moves. See if Alkermes can continue to rebound and hit that benchmark.</p>\n<hr/>\n<p>Can You Really Time The Stock Market? </p>\n<hr/>\n<p>Alkermes is trying to complete a cup without handle with a 32.88 buy point. See if the stock can break out in volume at least 40% above average.</p>\n<div><div></div></div>\n<p>The company reported negative growth for both the top and bottom lines last quarter. Alkermes is expected to release its next quarterly numbers on or around Oct. 23.</p>\n<p>The company holds the No. 19 rank among its peers in the Medical-Biomed/Biotech industry group. <b>ADMA Biologics</b> (ADMA), <b>Catalyst Pharmaceuticals</b> (CPRX) and <b>United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></b> (UTHR) are among the top 5 highly rated stocks within the group.</p>\n<p><strong>RELATED:</strong></p>\n<p>Biotech And Pharmaceutical Industry And Stock News</p>\n<p>Which Stocks Are Showing Improved Technical Action?</p>\n<p>Why Should You Use IBD's Relative Strength Rating?</p>\n<p>How Relative Strength Line Can Help You Judge A Stock</p>\n<p>Ready To Grow Your Investing Skills? Join An IBD Meetup Group!</p>\n</div></body></html>","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alkermes Shows Improved Relative Strength; Still Shy Of Benchmark</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlkermes Shows Improved Relative Strength; Still Shy Of Benchmark\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Blockhead</strong><span class=\"h-time small\">2024-10-14 15:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p>The Relative Strength (RS) Rating for <b>Alkermes</b> (ALKS) moved up into a new percentile Monday, as it got a lift from 64 to 76.</p>\n<span>\n<span>\n<span jw-video-key=\"ehvvvOwx\" vid-authors=\"RACHEL FOX\" vid-cat=\"Investor's Corner\" vid-date=\"01/23/2024\" vid-date-tmsp=\"1706014196\" vid-dom-id=\"8911995-670d5648cd096\" vid-id=\"8911995\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/01/IC_IPOstocks-640x360.png\" vid-name=\"How To Find The Best IPO Stocks\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/ehvvvOwx.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nHow To Find The Best IPO Stocks\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>How To Find The Best IPO Stocks</span>\n</span>\n</span>\n</span>\n</span>\n<p>IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.</p>\n<p>Decades of market research reveals that the best stocks often have an 80 or better RS Rating as they launch their largest price moves. See if Alkermes can continue to rebound and hit that benchmark.</p>\n<hr/>\n<p>Can You Really Time The Stock Market? </p>\n<hr/>\n<p>Alkermes is trying to complete a cup without handle with a 32.88 buy point. See if the stock can break out in volume at least 40% above average.</p>\n<div><div></div></div>\n<p>The company reported negative growth for both the top and bottom lines last quarter. Alkermes is expected to release its next quarterly numbers on or around Oct. 23.</p>\n<p>The company holds the No. 19 rank among its peers in the Medical-Biomed/Biotech industry group. <b>ADMA Biologics</b> (ADMA), <b>Catalyst Pharmaceuticals</b> (CPRX) and <b>United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></b> (UTHR) are among the top 5 highly rated stocks within the group.</p>\n<p><strong>RELATED:</strong></p>\n<p>Biotech And Pharmaceutical Industry And Stock News</p>\n<p>Which Stocks Are Showing Improved Technical Action?</p>\n<p>Why Should You Use IBD's Relative Strength Rating?</p>\n<p>How Relative Strength Line Can Help You Judge A Stock</p>\n<p>Ready To Grow Your Investing Skills? Join An IBD Meetup Group!</p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.investors.com/ibd-data-stories/alkermes-shows-improved-relative-strength-still-shy-of-benchmark/\">Blockhead</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1571399168.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","start_time":0,"source_url":"https://www.investors.com/ibd-data-stories/alkermes-shows-improved-relative-strength-still-shy-of-benchmark/","article_id":"2475137873","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU6-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475137873","pubTimestamp":1728889200,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"A Relative Strength Rating upgrade for Alkermes shows improving technical performance. Will it continue?","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","UTHR":"美国联合医疗","CPRX":"Catalyst Pharmaceutical Partners","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","ALKS":"阿尔凯默斯","BK4139":"生物科技","ADMA":"ADMA Biologics Inc","BK4006":"钢铁","BK4532":"文艺复兴科技持仓","RS":"Reliance Steel & Aluminum Co"},"translate_title":"Alkermes显示出改善的相对强度；仍低于基准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"ALKS":1,"CPRX":1,"RS":1,"UTHR":1},"content_text":"The Relative Strength (RS) Rating for Alkermes (ALKS) moved up into a new percentile Monday, as it got a lift from 64 to 76.\n\n\n\n↑\nX\n\n\n\n\nHow To Find The Best IPO Stocks\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Find The Best IPO Stocks\n\n\n\n\nIBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.\nDecades of market research reveals that the best stocks often have an 80 or better RS Rating as they launch their largest price moves. See if Alkermes can continue to rebound and hit that benchmark.\n\nCan You Really Time The Stock Market? \n\nAlkermes is trying to complete a cup without handle with a 32.88 buy point. See if the stock can break out in volume at least 40% above average.\n\nThe company reported negative growth for both the top and bottom lines last quarter. Alkermes is expected to release its next quarterly numbers on or around Oct. 23.\nThe company holds the No. 19 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX) and United Therapeutics (UTHR) are among the top 5 highly rated stocks within the group.\nRELATED:\nBiotech And Pharmaceutical Industry And Stock News\nWhich Stocks Are Showing Improved Technical Action?\nWhy Should You Use IBD's Relative Strength Rating?\nHow Relative Strength Line Can Help You Judge A Stock\nReady To Grow Your Investing Skills? Join An IBD Meetup Group!","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}